# Alnylam Pharmaceuticals Inc. (ALNY) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $266.11, market value $35.6 billion.

## Valuation
- **P/E (trailing): 46.3×** (5-yr avg 170.7×, 3-yr avg 170.7×). Alnylam Pharmaceuticals Inc. trades at 46.3× trailing earnings, well below its own five-year average of 170.7×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 21.1×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.10**. A PEG of 0.10 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 9.6×**. Each dollar of revenue is priced at 9.6×.
- **Price / book: 26.3×**. The shares trade at 26.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 62.1×**. Enterprise value is 62.1× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 1.3%** (5-yr avg -1.0%). Free cash flow equals 1.3% of the market value, above its five-year average of -1.0%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 2.2%**. The inverse of the P/E: 2.2% of the price is earned each year.

## Profitability
- **Operating margin: 13.5%**. 13.5% of revenue is left after running the business.
- **Net margin: 8.4%**. 8.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 39.8%**. 39.8% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: -206.0%**. Return on all capital, debt included, is -206.0%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 6.3%**. Each dollar of assets produces 6.3% of profit.

## Growth
- **Revenue growth (1 yr): 65.2%** (3-yr 53.0%/yr, 5-yr 49.8%/yr). Revenue grew 65.2% over the last year, against 49.8% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 206.9%**. Earnings per share rose 206.9%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.86**. Debt is 0.86 times equity, moderate leverage.
- **Net debt / EBITDA: net cash**. Alnylam Pharmaceuticals Inc. holds more cash than debt.
- **Current ratio: 2.76** (quick 2.76). Current assets cover the next year's liabilities 2.76 times.
- **Altman Z-score: 7.04**. A Z-score of 7.04 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Alnylam Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (26 analysts). 26 analysts cover Alnylam Pharmaceuticals Inc.; the consensus is buy, with an average price target of $370.20 (+39% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -41.3%** (YTD -33.1%, 3-mo -12.2%). The shares are down 41.3% over twelve months including dividends.
- **From 52-week high: -46.3%** (34.5% above the low). Trading 46% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 62**. An RSI of 62 is neutral.
- **Beta (1 yr): 0.33** (volatility 47%). Beta of 0.33 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ALNY · Page: https://foliofundamentals.com/stocks/alny

Not investment advice.